• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗性蛋白质聚集:机制、设计与控制。

Therapeutic protein aggregation: mechanisms, design, and control.

作者信息

Roberts Christopher J

机构信息

Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.

出版信息

Trends Biotechnol. 2014 Jul;32(7):372-80. doi: 10.1016/j.tibtech.2014.05.005. Epub 2014 Jun 4.

DOI:10.1016/j.tibtech.2014.05.005
PMID:24908382
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4146573/
Abstract

Although it is well known that proteins are only marginally stable in their folded states, it is often less well appreciated that most proteins are inherently aggregation-prone in their unfolded or partially unfolded states, and the resulting aggregates can be extremely stable and long-lived. For therapeutic proteins, aggregates are a significant risk factor for deleterious immune responses in patients, and can form via a variety of mechanisms. Controlling aggregation using a mechanistic approach may allow improved design of therapeutic protein stability, as a complement to existing design strategies that target desired protein structures and function. Recent results highlight the importance of balancing protein environment with the inherent aggregation propensities of polypeptide chains.

摘要

虽然众所周知蛋白质在其折叠状态下仅具有一定程度的稳定性,但人们往往不太了解的是,大多数蛋白质在其未折叠或部分未折叠状态下本质上易于聚集,并且所形成的聚集体可能极其稳定且寿命很长。对于治疗性蛋白质而言,聚集体是患者产生有害免疫反应的一个重要风险因素,并且可以通过多种机制形成。使用机械方法控制聚集可能有助于改进治疗性蛋白质稳定性的设计,作为针对所需蛋白质结构和功能的现有设计策略的补充。最近的研究结果突出了平衡蛋白质环境与多肽链固有聚集倾向的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/da7e21cd6060/nihms605916f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/2e691f261939/nihms605916f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/03a79c7d1bcb/nihms605916f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/da7e21cd6060/nihms605916f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/2e691f261939/nihms605916f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/03a79c7d1bcb/nihms605916f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d2/4146573/da7e21cd6060/nihms605916f3.jpg

相似文献

1
Therapeutic protein aggregation: mechanisms, design, and control.治疗性蛋白质聚集:机制、设计与控制。
Trends Biotechnol. 2014 Jul;32(7):372-80. doi: 10.1016/j.tibtech.2014.05.005. Epub 2014 Jun 4.
2
Driving Forces for Nonnative Protein Aggregation and Approaches to Predict Aggregation-Prone Regions.非天然蛋白质聚集的驱动力及预测聚集倾向区域的方法。
Annu Rev Chem Biomol Eng. 2017 Jun 7;8:139-159. doi: 10.1146/annurev-chembioeng-060816-101404.
3
Stability of an aggregation-prone partially folded state of human profilin-1 correlates with aggregation propensity.人原肌球蛋白-1 易聚集的部分折叠状态的稳定性与聚集倾向相关。
J Biol Chem. 2018 Jun 29;293(26):10303-10313. doi: 10.1074/jbc.RA118.002087. Epub 2018 May 14.
4
Solubis: a webserver to reduce protein aggregation through mutation.Solubis:一个通过突变减少蛋白质聚集的网络服务器。
Protein Eng Des Sel. 2016 Aug;29(8):285-9. doi: 10.1093/protein/gzw019. Epub 2016 Jun 9.
5
AGGRESCAN3D: Toward the Prediction of the Aggregation Propensities of Protein Structures.AGGRESCAN3D:迈向蛋白质结构聚集倾向预测
Methods Mol Biol. 2018;1762:427-443. doi: 10.1007/978-1-4939-7756-7_21.
6
Computational Design To Reduce Conformational Flexibility and Aggregation Rates of an Antibody Fab Fragment.计算设计以降低抗体 Fab 片段的构象灵活性和聚集速率。
Mol Pharm. 2018 Aug 6;15(8):3079-3092. doi: 10.1021/acs.molpharmaceut.8b00186. Epub 2018 Jun 22.
7
Engineering more stable proteins.工程化更稳定的蛋白质。
Chem Soc Rev. 2018 Dec 21;47(24):9026-9045. doi: 10.1039/c8cs00014j. Epub 2018 Oct 11.
8
Principles of Protein Stability and Their Application in Computational Design.蛋白质稳定性原理及其在计算设计中的应用。
Annu Rev Biochem. 2018 Jun 20;87:105-129. doi: 10.1146/annurev-biochem-062917-012102. Epub 2018 Jan 26.
9
Using protein engineering to understand and modulate aggregation.利用蛋白质工程来理解和调节聚集。
Curr Opin Struct Biol. 2020 Feb;60:157-166. doi: 10.1016/j.sbi.2020.01.005. Epub 2020 Feb 19.
10
Protein aggregation and its impact on product quality.蛋白质聚集及其对产品质量的影响。
Curr Opin Biotechnol. 2014 Dec;30:211-7. doi: 10.1016/j.copbio.2014.08.001. Epub 2014 Aug 28.

引用本文的文献

1
Exploring Protein Aggregation in Biological Products: From Mechanistic Understanding to Practical Solutions.探索生物制品中的蛋白质聚集:从机理理解到实际解决方案
AAPS PharmSciTech. 2025 Jul 8;26(6):189. doi: 10.1208/s12249-025-03189-2.
2
Physics of Protein Aggregation in Normal and Accelerated Brain Aging.正常与加速脑老化过程中蛋白质聚集的物理学
Bioessays. 2025 Aug;47(8):e70030. doi: 10.1002/bies.70030. Epub 2025 Jun 20.
3
Chemical synthesis uncovers the significant impact of natural glycosylation on islet amyloid polypeptide aggregation.

本文引用的文献

1
Physicochemical and functional characterization of vaccine antigens and adjuvants.疫苗抗原和佐剂的理化和功能特性分析。
Expert Rev Vaccines. 2014 May;13(5):671-85. doi: 10.1586/14760584.2014.907528. Epub 2014 Apr 4.
2
Competing aggregation pathways for monoclonal antibodies.单克隆抗体的竞争聚集途径。
FEBS Lett. 2014 Mar 18;588(6):936-41. doi: 10.1016/j.febslet.2014.01.051. Epub 2014 Feb 12.
3
Introduction to protein crystallization.蛋白质结晶简介。
化学合成揭示了天然糖基化对胰岛淀粉样多肽聚集的重大影响。
Sci Adv. 2025 Jun 20;11(25):eadx8201. doi: 10.1126/sciadv.adx8201. Epub 2025 Jun 18.
4
Impact of Initial Aggregate Level on Aggregation Potential of Monoclonal Antibodies in Different Buffer Systems.初始聚集体水平对不同缓冲体系中单克隆抗体聚集潜力的影响
Pharm Res. 2025 Jun 6. doi: 10.1007/s11095-025-03874-8.
5
A Review on the Stability Challenges of Advanced Biologic Therapeutics.先进生物治疗药物稳定性挑战综述
Pharmaceutics. 2025 Apr 23;17(5):550. doi: 10.3390/pharmaceutics17050550.
6
Assessing subvisible particle risks in monoclonal antibodies: insights from quartz crystal microbalance with dissipation, machine learning, and in silico analysis.评估单克隆抗体中的亚可见颗粒风险:来自具有耗散功能的石英晶体微天平、机器学习和计算机模拟分析的见解。
MAbs. 2025 Dec;17(1):2501629. doi: 10.1080/19420862.2025.2501629. Epub 2025 May 11.
7
Modification of aggregation-prone regions of Arabidopsis glutamyl-tRNA reductase leads to increased stability while maintaining enzyme activity.对拟南芥谷氨酰胺-tRNA还原酶易聚集区域的修饰导致稳定性增加,同时保持酶活性。
Front Plant Sci. 2025 Mar 13;16:1556843. doi: 10.3389/fpls.2025.1556843. eCollection 2025.
8
From Cell Clones to Recombinant Protein Product Heterogeneity in Chinese Hamster Ovary Cell Systems.从细胞克隆到中国仓鼠卵巢细胞系统中的重组蛋白产物异质性
Int J Mol Sci. 2025 Feb 4;26(3):1324. doi: 10.3390/ijms26031324.
9
Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening.利用高通量分析和自动化技术快速开发高浓度单克隆抗体制剂:集成辅料兼容性和粘度筛选
Antib Ther. 2024 Oct 12;7(4):335-350. doi: 10.1093/abt/tbae028. eCollection 2024 Oct.
10
Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics.混合质谱在抗体生物治疗药物生产中的应用
J Am Soc Mass Spectrom. 2025 Jan 1;36(1):44-57. doi: 10.1021/jasms.4c00253. Epub 2024 Nov 21.
Acta Crystallogr F Struct Biol Commun. 2014 Jan;70(Pt 1):2-20. doi: 10.1107/S2053230X13033141. Epub 2013 Dec 24.
4
What's fueling the biotech engine-2012 to 2013.是什么推动了生物技术引擎——2012年至2013年
Nat Biotechnol. 2014 Jan;32(1):32-9. doi: 10.1038/nbt.2794.
5
Significance of unfolding thermodynamics for predicting aggregation kinetics: a case study on high concentration solutions of a multi-domain protein.展开热力学对预测聚集动力学的意义:以一种多结构域蛋白质的高浓度溶液为例的研究
Pharm Res. 2014 Jun;31(6):1575-87. doi: 10.1007/s11095-013-1263-5. Epub 2014 Jan 8.
6
Protein misfolding and aggregation research: some thoughts on improving quality and utility.蛋白质错误折叠与聚集研究:关于提高质量和实用性的一些思考。
Biotechnol Prog. 2013 Sep-Oct;29(5):1109-15. doi: 10.1002/btpr.1812. Epub 2013 Oct 9.
7
Deamidation of asparagine to aspartate destabilizes Cu, Zn superoxide dismutase, accelerates fibrillization, and mirrors ALS-linked mutations.天冬酰胺脱酰胺作用使铜锌超氧化物歧化酶失稳,加速纤维形成,并反映出与 ALS 相关的突变。
J Am Chem Soc. 2013 Oct 23;135(42):15897-908. doi: 10.1021/ja407801x. Epub 2013 Oct 10.
8
Toward aggregation-resistant antibodies by design.通过设计实现抗聚集抗体。
Trends Biotechnol. 2013 Nov;31(11):612-20. doi: 10.1016/j.tibtech.2013.07.002. Epub 2013 Aug 7.
9
Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.温度和渗透剂对 IgG1 抗体竞争降解途径的影响。
J Pharm Sci. 2013 Oct;102(10):3556-66. doi: 10.1002/jps.23668. Epub 2013 Jul 19.
10
Measuring and modeling hemoglobin aggregation below the freezing temperature.测量和建模低于冻结温度的血红蛋白聚集。
J Phys Chem B. 2013 Aug 1;117(30):8939-46. doi: 10.1021/jp4035369. Epub 2013 Jul 18.